ArticleCancer immunology, immunotherapy : CII2018
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.
Erratum issued Registry-linked trialOpen access · greenAbstract readCase ReportsEvaluation Study
In one paragraph
Article in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01586403 (Transfer of Genetically Engineered Lymphocytes in Melanoma Patients), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Transfer of Genetically Engineered Lymphocytes in Melanoma Patients: A Phase 1 Dose Escalation Study
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis.Cancer immunology, immunotherapy : CII · 2023Pooled it
- Targeting PIM2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells.The Journal of clinical investigation · 2026Article
- Autologous T cell therapy for PRAMENature medicine · 2025Article
- The Evolving T Cell Receptor Recognition Code: The Rules Are More Like Guidelines.Immunological reviews · 2025Review
- A Computational Strategy for the Rapid Identification and Ranking of Patient-Specific T Cell Receptors Bound to Neoantigens.Macromolecular rapid communications · 2024Article
- Quantification of circulating TCR-engineered T cells targeting a human endogenous retrovirus post-adoptive transfer using nanoplate digital PCR.Molecular therapy. Methods & clinical development · 2024Article
- Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy.Experimental hematology & oncology · 2024Review
- T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome.Nature reviews. Drug discovery · 2023Review
- Creating an Innovative Artificial Intelligence-Based Technology (TCRact) for Designing and Optimizing T Cell Receptors for Use in Cancer Immunotherapies: Protocol for an Observational Trial.JMIR research protocols · 2023Article
- Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance.Cell reports · 2023Article
- Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.Molecular cancer · 2023Review
- A class-mismatched TCR bypasses MHC restriction via an unorthodox but fully functional binding geometry.Nature communications · 2022Article
- Review
- Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects.Frontiers in immunology · 2022Review
- Using molecular dynamics simulations to interrogate T cell receptor non-equilibrium kinetics.Computational and structural biotechnology journal · 2022Article
- A computational algorithm to assess the physiochemical determinants of T cell receptor dissociation kinetics.Computational and structural biotechnology journal · 2022Article
- Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy.International journal of molecular sciences · 2021Review
- Tumor rejection properties of gp100Molecular immunology · 2021Article
- Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response.Scientific reports · 2021Article
- HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells.Molecular therapy oncolytics · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
26 authors at 7 institutions in 1 country.
Tamson MooreDepartment of Surgery, Loyola University Chicago, 2160 S. 1st Avenue, Maywood, IL, 60153, USA. tamoore@luc.edu.ORCID http://orcid.org/0000-0003-3770-3503
Courtney Regan WagnerDepartment of Medicine, Loyola University Chicago, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Gina M ScurtiDepartment of Surgery, Loyola University Chicago, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Kelli A HutchensDepartment of Pathology, Loyola University Chicago, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Constantine GodellasDepartment of Surgery, Loyola University Chicago, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Ann Lau ClarkDepartment of Medicine, Loyola University Chicago, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Elizabeth Motunrayo KolawoleO. Wayne Rollins Research Center, Emory University, Room 3127, 1510 Clifton Road NE, Atlanta, GA, 30322, USA.
Lance M HellmanDepartment of Chemistry & Biochemistry and the Harper Cancer Research Institute, University of Notre Dame, 251 Nieuwland Science Hall, Notre Dame, IN, 46656, USA.
Nishant K SinghDepartment of Chemistry & Biochemistry and the Harper Cancer Research Institute, University of Notre Dame, 251 Nieuwland Science Hall, Notre Dame, IN, 46656, USA.
Fernando A HuykeDepartment of Chemistry & Biochemistry and the Harper Cancer Research Institute, University of Notre Dame, 251 Nieuwland Science Hall, Notre Dame, IN, 46656, USA.
Siao-Yi WangDepartment of Surgery, Loyola University Chicago, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Kelly M CalabreseDepartment of Surgery, Loyola University Chicago, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Heather D EmbreeLentigen Technology Inc, A Miltenyi Biotec Company, 910 Clopper Road Suite 200S, Gaithersburg, MD, 20878, USA.
Rimas OrentasLentigen Technology Inc, A Miltenyi Biotec Company, 910 Clopper Road Suite 200S, Gaithersburg, MD, 20878, USA.
Keisuke ShiraiHollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas St, Charleston, SC, 29425, USA.
Emilia DellaceccaDepartment of Pathology, Loyola University Chicago, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Elizabeth Garrett-MayerHollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas St, Charleston, SC, 29425, USA.
Mingli LiHollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas St, Charleston, SC, 29425, USA.
Jonathan M EbyDepartment of Pathology, Loyola University Chicago, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Patrick J StiffDepartment of Medicine, Loyola University Chicago, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Brian D EvavoldO. Wayne Rollins Research Center, Emory University, Room 3127, 1510 Clifton Road NE, Atlanta, GA, 30322, USA.
Brian M BakerDepartment of Chemistry & Biochemistry and the Harper Cancer Research Institute, University of Notre Dame, 251 Nieuwland Science Hall, Notre Dame, IN, 46656, USA.
I Caroline Le PooleDepartment of Pathology, Loyola University Chicago, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Boro DropulicLentigen Technology Inc, A Miltenyi Biotec Company, 910 Clopper Road Suite 200S, Gaithersburg, MD, 20878, USA.
Joseph I ClarkDepartment of Medicine, Loyola University Chicago, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Michael I NishimuraDepartment of Surgery, Loyola University Chicago, 2160 S. 1st Avenue, Maywood, IL, 60153, USA.
Loyola University Chicago · USUniversity of Notre Dame · USLentigen Technology (United States) · USEmory University · USMedical University of South Carolina · USDartmouth–Hitchcock Medical Center · USNorthwestern University · US
Funding
TCR TRANSDUCED CDB T CELLS FOR ADOPTIVE IMMUNOTHERAPYP01CA154778 · NCI · LOYOLA UNIVERSITY CHICAGO · PI NISHIMURA, MICHAEL I. · 2011 to 2015
$15.4MClinical Vector for TCR Immunotherapy Targeted to MelanomaR44CA126461 · NCI · LENTIGEN CORPORATION · PI DROPULIC, BORO · 2010 to 2012
$5.1MBuilding better T cell receptors for targeted immunotherapyR01AI129543 · NIAID · UNIVERSITY OF NOTRE DAME · PI BAKER, BRIAN M, NISHIMURA, MICHAEL I. · 2017 to 2021
$3.8MEvolution of CD8+ TCR affinity during chronic viral infectionR01AI096879 · NIAID · EMORY UNIVERSITY · PI EVAVOLD, BRIAN D · 2012 to 2016
$2.1MTCR Affinity and Therapeutic Efficacy of T CellsR01CA104947 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI NISHIMURA, MICHAEL I. · 2007 to 2011
$1.9MSeparating autoimmunity and anti-tumor immunityR01CA191317 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LE POOLE, I. CAROLINE · 2015 to 2019
$1.8MTumor Recognition by TCR Transduced CD4+ and CD8+T CellsR01CA090873 · NCI · UNIVERSITY OF CHICAGO · PI NISHIMURA, MICHAEL I · 2001 to 2004
$1.3MLentiviral Vectors for TCR Immunotherapy Targeted to melanomaR43CA126461 · NCI · LENTIGEN CORPORATION · PI DROPULIC, BORO · 2006 to 2006
$243kNCI NIH HHS P01 CA154778NCI NIH HHS R01 CA090873NCI NIH HHS R01 CA104947NCI NIH HHS R01 CA191317NCI NIH HHS R43 CA126461NCI NIH HHS R44 CA126461NIAID NIH HHS R01 AI096879NIAID NIH HHS R01 AI129543NIH HHS P01 CA154778NIH HHS R01 AI096879NIH HHS R01 AI129543-01NIH HHS R01 CA104947NIH HHS R01 CA104947-S1NIH HHS R01 CA90873NIH HHS R43 CA126461NIH HHS R44 CA126461
Abstract
Malignant melanoma incidence has been increasing for over 30 years, and despite promising new therapies, metastatic disease remains difficult to treat. We describe preliminary results from a Phase I clinical trial (NCT01586403) of adoptive cell therapy in which three patients received autologous CD4
Indexed as
AdultAgedAntigens, NeoplasmHumansMaleMelanomaMiddle AgedNeoplasm MetastasisPrognosisReceptors, Antigen, T-CellSkin NeoplasmsT-Lymphocyte SubsetsTransplantation, AutologousAntigens, NeoplasmReceptors, Antigen, T-CellAdoptive transferClinical trialImmunotherapyMetastatic melanomaTransduced T cellsVitiligo
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT01586403ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.